keyword
MENU ▼
Read by QxMD icon Read
search

Everolimus AND aging

keyword
https://www.readbyqxmd.com/read/28077803/gerosuppression-by-pan-mtor-inhibitors
#1
Olga V Leontieva, Mikhail V Blagosklonny
Rapamycin slows organismal aging and delays age-related diseases, extending lifespan in numerous species. In cells, rapamycin and other rapalogs such as everolimus suppress geroconversion from quiescence to senescence. Rapamycin inhibits some, but not all, activities of mTOR. Recently we and others demonstrated that pan-mTOR inhibitors, known also as dual mTORC1/C2 inhibitors, suppress senescent phenotype. As a continuation of these studies, here we investigated in detail a panel of pan-mTOR inhibitors, to determine their optimal gerosuppressive concentrations...
December 30, 2016: Aging
https://www.readbyqxmd.com/read/28076449/long-term-follow-up-of-patients-after-percutaneous-coronary-intervention-with-everolimus-eluting-bioresorbable-vascular-scaffold
#2
Rafael Alexandre Meneguz-Moreno, José de Ribamar Costa, Freddy Antônio Britto Moscoso, Rodolfo Staico, Luiz Fernando Leite Tanajura, Marinella Patrizia Centemero, Auréa Jacob Chaves, Andrea Claudia Leão de Sousa Abizaid, Amanda Guerra de Moraes Rego E Sousa, Alexandre Antonio Cunha Abizaid
Background: Bioresorbable vascular scaffolds (BVS) were developed to improve the long-term results of percutaneous coronary intervention, restoring vasomotion. Objectives: To report very late follow-up of everolimus-eluting Absorb BVS (Abbott Vascular, Santa Clara, USA) in our center. Methods: Observational retrospective study, in a single Brazilian center, from August 2011 to October 2013, including 49 patients submitted to Absorb BVS implantation...
January 9, 2017: Arquivos Brasileiros de Cardiologia
https://www.readbyqxmd.com/read/28043164/current-treatment-options-and-investigational-drugs-for-waldenstrom-s-macroglobulinemia
#3
Maria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis, Meletios A Dimopoulos
Waldenström's Macroglobulinemia (WM) is a rare, indolent, incurable, low-grade B-cell lymphoplasmacytic neoplasm. This review article provides a modern clinical perspective of the individualized management of patients with symptomatic WM, in the context of the updated treatment guidelines and the currently available trial data. Areas covered: Rituximab-based regimens (such as the dexamethasone, rituximab and cyclophosphamide combination, DRC) are the most widely used in the management of both newly diagnosed and relapsed/refractory patients with WM...
January 3, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28038806/bioresorbable-coronary-stent-for-the-treatment-of-complex-coronary-lesions-data-from-an-all-comer-registry
#4
Andrea Cuculo, Antonio Ruggiero, Antonio Centola, Giulio Campanale, Tommaso Passero, Antonio Gaglione, Matteo Di Biase, Natale Daniele Brunetti
BACKGROUND: The study aimed to report the results from an all-comers registry of patients undergoing coronary angioplasty and treated with bioresorbable vascular scaffold (BVS). METHODS: Fifty-five consecutive patients with type B/C coronary lesions according to the AHA classification and treated with BVS were enrolled in the study. The clinical and procedural characteristics of enrolled patients were recorded. Fifty-five consecutive subjects with coronary lesions type B/C treated with everolimus eluting stent (EES) were used as control group...
December 19, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/28017311/efficacy-and-safety-of-the-absorb-everolimus-eluting-bioresorbable-scaffold%C3%A2-for-treatment-of-patients%C3%A2-with%C3%A2-diabetes-mellitus-results-of-the-absorb-diabetic-substudy
#5
Dean J Kereiakes, Stephen G Ellis, Takeshi Kimura, Alexandre Abizaid, Weiying Zhao, Susan Veldhof, Minh-Thien Vu, Zhen Zhang, Yoshinobu Onuma, Bernard Chevalier, Patrick W Serruys, Gregg W Stone
OBJECTIVES: The study sought to evaluate the efficacy and safety of the Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) (Abbott Vascular, Abbott Park, Illinois) in patients with diabetes mellitus. BACKGROUND: Randomized, controlled trials have demonstrated comparable clinical outcomes following percutaneous coronary intervention with either Absorb BVS or metallic Xience everolimus-eluting stent. However, these trials lack power required to provide reliable treatment effect estimates in this high-risk population...
December 1, 2016: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/27974669/initial-experience-of-bioabsorbable-polymer-everolimus-eluting-synergy-stents-in-high-risk-patients-undergoing-complex-percutaneous-coronary-intervention-with-early-discontinuation-of-dual-antiplatelet-therapy
#6
Rebecca L Noad, Colm G Hanratty, Simon J Walsh
AIMS: As more elderly and co-morbid patients require percutaneous revascularization, 1 year of dual-antiplatelet therapy (DAPT) becomes concerning. Synergy stents (Boston Scientific) allow for early cessation of DAPT. This study assessed those in our unit who underwent percutaneous coronary intervention (PCI) with a Synergy stent to examine a minimum of 6 months of clinical outcomes after early discontinuation of DAPT. METHODS AND RESULTS: All non-trial patients in our unit who had PCI with a Synergy stent from August 2013 to February 2016 were retrospectively analyzed...
15, 2016: Journal of Invasive Cardiology
https://www.readbyqxmd.com/read/27928256/one-year-outcome-of-everolimus-eluting-stents-versus-biolimus-eluting-stents-in-patients-undergoing-percutaneous-coronary-intervention
#7
Mohammad Alidoosti, Vahideh Sharifnia, Seyed Ebrahim Kassaian, Alimohammad Hajizeinali, Hamidreza Poorhosseini, Mojtaba Salarifar, Younes Nozari, Elham Hakki Kazazi
Background: The biolimus-eluting stent (BES), with a biodegradable polymer, has not been previously compared with the everolimus-eluting stent (EES), as a second-generation drug-eluting stent (DES).We sought to compare the 1-year outcome between the PROMUS(™) stent (EES type) and the BioMatrix(™) stent (BES type). Methods: From March 2008 to September 2011, all patients treated with the PROMUS™ stent or the BioMatrix™ stent for coronary artery stenosis at Tehran Heart Center were enrolled. The primary end points were 1-year adverse events, comprising death, myocardial infarction, target vessel revascularization, and target lesion revascularization...
April 13, 2016: Journal of Tehran Heart Center
https://www.readbyqxmd.com/read/27918762/alternating-treatment-with-pazopanib-and-everolimus-vs-continuous-pazopanib-to-delay-disease-progression-in-patients-with-metastatic-clear-cell-renal-cell-cancer-the-ropetar-randomized-clinical-trial
#8
Geert A Cirkel, Paul Hamberg, Stefan Sleijfer, Olaf J L Loosveld, M Wouter Dercksen, Maartje Los, Marco B Polee, Franchette van den Berkmortel, Maureen J Aarts, Laurens V Beerepoot, Gerard Groenewegen, Martijn P Lolkema, Metin Tascilar, Johanna E A Portielje, Frank P J Peters, Heinz-Josef Klümpen, Vincent van der Noort, John B A G Haanen, Emile E Voest
Importance: To our knowledge, this is the first randomized clinical trial evaluating an alternating treatment regimen in an attempt to delay disease progression in clear cell renal cell carcinoma. Objective: To test our hypothesis that an 8-week rotating treatment schedule with pazopanib and everolimus delays disease progression, exhibits more favorable toxic effects, and improves quality of life when compared with continuous treatment with pazopanib. Design, Setting, and Participants: This was an open-label, randomized (1:1) study (ROPETAR trial)...
December 1, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27893038/targeting-the-pi3k-akt-mtor-pathway-for-the-treatment-of-mesenchymal-triple-negative-breast-cancer-evidence-from-a-phase-1-trial-of-mtor-inhibition-in-combination-with-liposomal-doxorubicin-and-bevacizumab
#9
Reva K Basho, Michael Gilcrease, Rashmi K Murthy, Thorunn Helgason, Daniel D Karp, Funda Meric-Bernstam, Kenneth R Hess, Shelley M Herbrich, Vicente Valero, Constance Albarracin, Jennifer K Litton, Mariana Chavez-MacGregor, Nuhad K Ibrahim, James L Murray, Kimberly B Koenig, David Hong, Vivek Subbiah, Razelle Kurzrock, Filip Janku, Stacy L Moulder
Importance: Triple-negative breast cancer (TNBC) classified by transcriptional profiling as the mesenchymal subtype frequently harbors aberrations in the phosphoinositide 3-kinase (PI3K) pathway, raising the possibility of targeting this pathway to enhance chemotherapy response. Up to 30% of mesenchymal TNBC can be classified histologically as metaplastic breast cancer, a chemorefractory group of tumors with a mixture of epithelial and mesenchymal components identifiable by light microscopy...
November 23, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27878332/accelerated-cardiac-rhabdomyoma-regression-with-everolimus-in-infants-with-tuberous-sclerosis-complex
#10
Fatou Aw, Isabelle Goyer, Marie-Josée Raboisson, Christine Boutin, Philippe Major, Nagib Dahdah
Tuberous sclerosis complex is associated with benign tumors such as cardiac rhabdomyomas (RHM) caused by the disinhibition of the mammalian target of rapamycin (mTOR) protein. Recent reports on everolimus, an mTOR inhibitor, have shown size reduction of RHM. We compared cases recently treated with everolimus to historic controls whose first echocardiography was within first month of life. The largest dimension of the largest RHM was reported as a percentage compared to the earliest echocardiography study. Treatment of the four cases was started at a median age of 6...
November 23, 2016: Pediatric Cardiology
https://www.readbyqxmd.com/read/27860334/maintenance-therapy-with-everolimus-for-subependymal-giant-cell-astrocytoma-in-patients-with-tuberous-sclerosis-the-eminents-study
#11
Joanna Trelinska, Iwona Dachowska, Dobromila Baranska, Konrad Stawiski, Katarzyna Kotulska, Wojciech Fendler, Sergiusz Jozwiak, Wojciech Mlynarski
OBJECTIVE: One of the therapeutic options for patients with tuberous sclerosis (TCS) and subependymal giant cell astrocytoma (SEGA) is everolimus treatment once daily, every day, to attain trough concentrations of 5-15 ng/ml (standard treatment). The aim of this study was to evaluate the efficacy and safety of a reduced dose of everolimus (three times a week with a daily dose as in standard treatment-maintenance therapy) in a group of patients who were previously treated with standard dose for at least 12 months...
November 15, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27815344/sealing-intermediate-nonobstructive-coronary-saphenous-vein-graft-lesions-with-drug-eluting-stents-as-a-new-approach-to-reducing-cardiac-events-a-randomized-controlled-trial
#12
Josep Rodés-Cabau, Sanjit S Jolly, John Cairns, Samer Mansour, Philippe L L'Allier, Patrick J Teefy, John J Graham, Michel R Le May, Warren J Cantor, David Wood, Kumar Balasubramanian, Robert DeLarochellière, Vlad Dzavik
BACKGROUND: The objective of this study was to assess the efficacy of sealing intermediate nonobstructive coronary saphenous vein graft (SVG) lesions with drug-eluting stents (DES; paclitaxel- or everolimus-eluting stents) for reducing major adverse cardiac events (MACE). METHODS AND RESULTS: This was a randomized controlled multicenter clinical trial that enrolled patients with a previous coronary artery bypass graft who had developed at least 1 intermediate nonobstructive SVG lesion (30%-60% diameter stenosis by visual estimation)...
November 2016: Circulation. Cardiovascular Interventions
https://www.readbyqxmd.com/read/27809914/efficacy-and-safety-of-everolimus-in-children-with-tsc-associated-epilepsy-pilot-data-from-an-open-single-center-prospective-study
#13
Sharon Samueli, Klaus Abraham, Anastasia Dressler, Gudrun Gröppel, Angelika Mühlebner-Fahrngruber, Theresa Scholl, Gregor Kasprian, Franco Laccone, Martha Feucht
BACKGROUND: Epilepsy occurs in up to 90 % of all individuals with tuberous sclerosis complex (TSC). In 67 % disease onset is during childhood. In ≥ 50 % seizures are refractory to currently available treatment options. The mTOR-Inhibitor Everolimus (Votubia®) was approved for the treatment of subependymal giant cell astrocytoma (SEGA) and renal angiomyolipoma (AML) in Europe in 2011. It's anticonvulsive/antiepileptic properties are promising, but evidence is still limited. Study aim was to evaluate the efficacy and safety of Everolimus in children and adolescents with TSC-associated epilepsies...
November 3, 2016: Orphanet Journal of Rare Diseases
https://www.readbyqxmd.com/read/27806902/very-thin-strut-biodegradable-polymer-everolimus-eluting-and-sirolimus-eluting-stents-versus-durable-polymer-zotarolimus-eluting-stents-in-allcomers-with-coronary-artery-disease-bio-resort-a-three-arm-randomised-non-inferiority-trial
#14
Clemens von Birgelen, Marlies M Kok, Liefke C van der Heijden, Peter W Danse, Carl E Schotborgh, Martijn Scholte, R Melvyn Tjon Joe Gin, Samer Somi, K G van Houwelingen, M G Stoel, Frits H A F de Man, J Hans W Louwerenburg, Marc Hartmann, Paolo Zocca, Gerard C M Linssen, Job van der Palen, Carine J M Doggen, Marije M Löwik
BACKGROUND: In patients with coronary artery disease, treated with durable polymer-coated drug-eluting stents, the life-long presence of the polymer might delay arterial healing. Novel very thin strut biodegradable polymer stents, which leave only a bare metal stent after polymer resorption, might improve long-term outcome. We investigated in allcomers the safety and efficacy of three stents eluting either everolimus, sirolimus, or zotarolimus, often clinically used but never compared, of which the biodegradable polymer everolimus-eluting stent was never before assessed in allcomers...
November 26, 2016: Lancet
https://www.readbyqxmd.com/read/27806897/comparison-of-an-everolimus-eluting-bioresorbable-scaffold-with-an-everolimus-eluting-metallic-stent-for-the-treatment-of-coronary-artery-stenosis-absorb-ii-a-3-year-randomised-controlled-single-blind-multicentre-clinical-trial
#15
Patrick W Serruys, Bernard Chevalier, Yohei Sotomi, Angel Cequier, Didier Carrié, Jan J Piek, Ad J Van Boven, Marcello Dominici, Dariusz Dudek, Dougal McClean, Steffen Helqvist, Michael Haude, Sebastian Reith, Manuel de Sousa Almeida, Gianluca Campo, Andrés Iñiguez, Manel Sabaté, Stephan Windecker, Yoshinobu Onuma
BACKGROUND: No medium-term data are available on the random comparison between everolimus-eluting bioresorbable vascular scaffolds and everolimus-eluting metallic stents. The study aims to demonstrate two mechanistic properties of the bioresorbable scaffold: increase in luminal dimensions as a result of recovered vasomotion of the scaffolded vessel. METHODS: The ABSORB II trial is a prospective, randomised, active-controlled, single-blind, parallel two-group, multicentre clinical trial...
November 19, 2016: Lancet
https://www.readbyqxmd.com/read/27798900/what-characterizes-long-term-survivors-of-recurrent-ovarian-cancer-case-report-and-review-of-the-literature
#16
Ziad Hilal, Beate Schultheis, Franziska Hartmann, Askin Dogan, Cem Cetin, Harald Krentel, Sven Schiermeier, Clemens B Tempfer
BACKGROUND: Women with recurrent ovarian cancer have a poor prognosis and short survival. However, some women are long-term survivors and it is unclear whether they share specific common characteristics. CASE REPORT: We present the case of a 63-year-old woman with histologically-proven recurrent ovarian cancer and a survival time of 16 years after the diagnosis of recurrence. She underwent initial debulking surgery in 1994, followed by 6 cycles of adjuvant chemotherapy with cisplatin and paclitaxel...
2016: Anticancer Research
https://www.readbyqxmd.com/read/27798513/longitudinal-pharmacokinetics-of-everolimus-when-combined-with-low-level-of-tacrolimus-in-elderly-renal-transplant-recipients
#17
Elias David-Neto, Fabiana Agena, Fernanda Ramos, Ana Heloisa Triboni, Paschoalina Romano, Persio de Almeida Rezende Ebner, Venceslau Coelho, Nelson Zocoler Galante, Francine Carvalinho Lemos
BACKGROUND: Although the proportion of elderly patients among renal transplant recipients has increased, pharmacokinetic (PK) studies of immunosuppressants rarely include older patients. METHODS: We studied 12-hours everolimus (EVL) PK in 16 elderly renal transplant recipients (all caucasians; 10 males; mean age, 64±2 years, (61-71y), in 4 separate time-points (at 7, 30, 60 and 150 days) after EVL introduction, corresponding to a mean post renal-transplantation day: PK1 (43±4days), PK2 (65±7 days), PK3 (106±17 days) and PK4 (206±40 days)...
October 28, 2016: Transplantation
https://www.readbyqxmd.com/read/27797585/beneficial-effects-of-everolimus-on-autism-and-attention-deficit-hyperactivity-disorder-symptoms-in-a-group-of-patients-with-tuberous-sclerosis-complex
#18
Ayse Kilincaslan, Burcu Ece Kok, Pinar Tekturk, Cengiz Yalcinkaya, Cigdem Ozkara, Zuhal Yapici
OBJECTIVES: Such neuropsychiatric symptoms as autism spectrum disorders, attention-deficit/hyperactivity disorder (ADHD), intellectual disability, aggression, and epilepsy are very common in patients with tuberous sclerosis complex (TSC). Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, is a recent and effective treatment for TSC patients with giant cell astrocytomas and renal angiomyolipoma, and it has been shown to have a potential to reduce tumor volume. However, there is a paucity of studies on the effects of everolimus on neuropsychiatric symptoms...
October 31, 2016: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/27681252/is-bioresorbable-vascular-scaffold-acute-recoil-affected-by-baseline-renal-function-and-scaffold-selection
#19
Haci Murat Gunes, Filiz Kizilirmak Yılmaz, Tayyar Gokdeniz, Gultekin Gunhan Demir, Ekrem Guler, Gamze Babur Guler, Oğuz Karaca, Beytullah Cakal, Ersin İbişoğlu, Bilal Boztosun
OBJECTIVE: The aim of the present study was to investigate the relationship between glomerular filtration rate (GFR) and acute post-scaffold recoil (PSR) in patients undergoing bioresorbable scaffold (BVS) implantation. METHODS: We included 130 patients who underwent everolimus-eluting BVS device (Absorb BVS; Abbott Vascular, Santa Clara, CA, USA) or the novolimus-eluting BVS device (Elixir Medical Corporation) implantations for single or multi-vessel disease. Clinical, angiographic variables and procedural characteristics were defined and pre-procedural GFR was calculated for each patient...
September 20, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27680407/open-label-phase-2-trial-of-first-line-everolimus-monotherapy-in-patients-with-papillary-metastatic-renal-cell-carcinoma-raptor-final-analysis
#20
Bernard Escudier, Vincent Molinie, Sergio Bracarda, Pablo Maroto, Cezary Szczylik, Paul Nathan, Sylvie Negrier, Claudia Weiss, Camillo Porta, Viktor Grünwald, Laurence Albiges
BACKGROUND: Papillary histology accounts for 10-15% of renal cell carcinoma (RCC), and treatment options for patients with this subtype are limited. The RAPTOR (RAD001 in Advanced Papillary Tumor Program in Europe; ClinicalTrials.gov, NCT00688753) study evaluated first-line everolimus in patients with papillary metastatic RCC (mRCC). METHODS: This phase 2 trial enrolled previously untreated patients with type 1 or type 2 papillary mRCC. Papillary histology was confirmed by central review and was performed for every patient...
September 24, 2016: European Journal of Cancer
keyword
keyword
50383
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"